news
Monoclonal antibody combination treatment given NICE approval
Shown to increase myeloma remission times by more than two years, a combination treatment that uses a monoclonal antibody has been approved by NICE.
List view / Grid view
Myeloma
news
Almost 400 cell and gene therapies in US pipeline, finds report
New research has found that there are 362 cell and gene therapies in clinical pipelines in the US, an increase from 2018.
news
SMC recommends three new medicines for routine use
The Scottish Medicines Consortium has published advice accepting three new medicines for routine use...
article
Treating multiple myeloma: An interview with Janssen
17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA
We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...
news
Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab)
24 August 2016 | By Janssen-Cilag International NV
Phase 3 data supporting submission suggests potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for relapsed multiple myeloma patients...
news
First-in-human trial of MundiPharma’s EDO-S101 starts
14 July 2016 | By Victoria White, Digital Content Producer
A first in class, fusion molecule, S101 is currently being developed for the treatment of relapsed-refractory haematological malignances...
news
EC approves extended indication for Kyprolis in multiple myeloma
4 July 2016 | By Victoria White, Digital Content Producer
The EC has approved a variation to the marketing authorisation for Amgen’s Kyprolis (carfilzomib) to include use in combination with dexamethasone alone...
news
First patient treated in fourth dose level NKR-2 Phase I/IIa trial
23 June 2016 | By Victoria White, Digital Content Producer
The study is evaluating Celyad's NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma...
news
Amgen presents new data for Kyprolis in multiple myeloma at EHA
13 June 2016 | By Victoria White, Digital Content Producer
A post-hoc analysis of the Phase III ASPIRE study highlighted the benefit of continued treatment with Kyprolis, lenalidomide and dexamethasone (KRd)...
news
Daratumumab significantly extends PFS in multiple myeloma study
10 June 2016 | By Victoria White, Digital Content Producer
A Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death...
news
Daratumumab extends PFS in patients with multiple myeloma
6 June 2016 | By Victoria White, Digital Content Producer
Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death...
news
Amgen receives positive CHMP opinion to extend indication of Kyprolis
27 May 2016 | By Victoria White, Digital Content Producer
The CHMP has adopted a positive opinion to extend the indication for Kyprolis to include treatment in combination with dexamethasone in multiple myeloma...
news
EC grants conditional approval to daratumumab in multiple myeloma
23 May 2016 | By Victoria White, Digital Content Producer
Daratumumab is the first CD38-directed mAb approved in Europe. It binds to CD38, a signalling molecule expressed on the surface of multiple myeloma cells...
news
EC approves Empliciti as combination therapy for multiple myeloma
12 May 2016 | By Victoria White, Digital Content Producer
Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy...
news
Daratumumab combination improves PFS in multiple myeloma study
1 April 2016 | By Victoria White
Daratumumab combination treatment regimen improved progression-free survival compared with bortezomib and dexamethasone alone...
